Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($1.21), $1.04 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $7.35 million versus the consensus estimate of $9.76 million.

“The fourth quarter marked considerable commercial, clinical and regulatory progress for the Company,” said Antony Mattessich, President and Chief Executive Officer. “Physician interest in DEXTENZA® remains high, and despite the challenging backdrop of COVID, adoption by ASCs and HOPDs continues to drive strong growth in reported sales. In the fourth quarter of 2020, in-market purchases were in excess of 14,000 billable units, representing sequential quarterly growth of greater than 40%. Beyond DEXTENZA, we have a unique pipeline of ophthalmology product candidates that each target indications within multi-billion dollar segments of the ophthalmology market. In 2021 we look forward to initiating multiple Phase 2 programs.”

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.